Esperion Therapeutics Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Esperion Therapeutics Inc (ESPR) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Esperion Therapeutics Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 418M vs 564,846M combined for its competitors (0.1% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-23.4% annualized vs trailing 12 months), vs decelerating (-6.7%) for its tracked peer group.
- Growth: Esperion Therapeutics Inc generated 23.3% revenue growth year over year in Q1 2026, vs 12.4% for its competitors combined.
- Profitability: Its -31.5% net margin compares with 12.9% for the peer group.
- Peer revenue share: Esperion Therapeutics Inc accounted for 0.1% of combined revenue among its tracked peer group, up from 0.1% a year earlier.
- Peer differentiation: Revenue per employee of $1.42M compares with $1.05M for the peer group (1.3x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
ESPR Sales vs. its Competitors, Q1 2026
Esperion Therapeutics Inc reported revenue growth of 23.25 % year on year in Q1 2026, above its competitors' combined revenue growth of 12.41 %.
With a net margin of -31.45 %, Esperion Therapeutics Inc reported lower profitability than its competitors (12.89 %).
Esperion Therapeutics Inc generated 0.06 % of the combined sales of its peer group, up from 0.06 % a year earlier.
API endpoints for this dataset
Esperion Therapeutics Inc vs. its Competitors, Q1 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Esperion Therapeutics Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Esperion Therapeutics Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Esperion Therapeutics Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (1) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Esperion Therapeutics Inc's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 9.0% year over year, combined, vs 23.3% for Esperion Therapeutics Inc. Esperion Therapeutics Inc's share of combined industry revenue moved from 0.01% to 0.02%, a gain of 0.00 percentage points.
Esperion Therapeutics Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Esperion Therapeutics Inc | No | Yes | Yes | Yes |
| Competitors combined (180) | ||||
| High-Confidence Competitors (1) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
ESPR Stock Performance relative to its Competitors
ESPR Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Gt Biopharma Inc | 282.9% | Outperformed |
| 2 | Sellas Life Sciences Group Inc | 282.9% | Outperformed |
| 3 | Damora Therapeutics Inc | 282.9% | Outperformed |
| 4 | Spyre Therapeutics Inc | 282.9% | Outperformed |
| 5 | Gossamer Bio Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Esperion Therapeutics Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Esperion Therapeutics Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Esperion Therapeutics Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Esperion Therapeutics Inc |
799.30 | 418.24 |
 Eli Lilly And Company |
1,279,607.89 | 86,462.00 |
 Akari Therapeutics Plc |
846,737.51 | - |
 Johnson and Johnson |
687,517.91 | 99,335.00 |
 Abbvie Inc |
520,773.08 | 66,014.00 |
 Merck and Co Inc |
365,658.80 | 66,569.00 |
| SUBTOTAL | 5,705,519.68 | 776,444.15 |
Sign in to see all competitors of Esperion Therapeutics Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Esperion Therapeutics Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Esperion Therapeutics Inc's Competitors Named by the Company
Competitive relationships identified from Esperion Therapeutics Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Alnylam Pharmaceuticals Inc | Company report | 85% |
| Eli Lilly And Company | Company report | 85% |
| Novartis Ag | Company report | 85% |
| Bristol myers Squibb Company | Company report | 85% |
| Pfizer Inc | Company report | 85% |
| Amarin Corp Plcuk | Company report | 85% |
| Merck and Co Inc | Company report | 85% |
| Abbvie Inc | Company report | 85% |
| Galapagos Nv | Company report | 85% |
| Astrazeneca Plc | Company report | 85% |
| Amgen Inc | Company report | 85% |
| Sanofi | Company report | 85% |
| Vertex Pharmaceuticals Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Esperion Therapeutics Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Esperion Therapeutics Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Eli Lilly And Company | Reportable 100.00 % |
| Johnson and Johnson | Oncology 29.93 % |
| Merck and Co Inc | Pharmaceutical segment 89.95 % |
| Amgen Inc | Reportable 100.00 % |
| Pfizer Inc | U.S. Commercial Division 58.35 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Esperion Therapeutics Inc .
Esperion Therapeutics Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Esperion Therapeutics Inc | 799 | 1,422,599 | -25,248 |
| Eli Lilly And Company | 1,279,608 | 1,729,240 | 551,594 |
| Akari Therapeutics Plc | 846,738 | - | -4,674,667 |
| Johnson and Johnson | 687,518 | 705,504 | 114,311 |
| Abbvie Inc | 520,773 | 1,158,140 | 181,509 |
| Merck and Co Inc | 365,659 | 887,587 | 42,267 |
| PEERS TOTAL | 5,704,720 | 1,054,945 | 167,529 |
Sign in to see all peers for Esperion Therapeutics Inc .
Esperion Therapeutics Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Eli Lilly And Company | United States 62.04 % |
| Johnson and Johnson | United States 58.90 % |
| Merck and Co Inc | EMEA 21.50 % |
| Pfizer Inc | United States 63.93 % |
| Vertex Pharmaceuticals Inc | United States 63.04 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Esperion Therapeutics Inc .
Esperion Therapeutics Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 491 companies in Esperion Therapeutics Inc's industry classification, broader than the peer set above. Market cap in millions of $.Esperion Therapeutics Inc ranks #0 of 491 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 983, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,267,410 | 23.79 % |
| 2 | Johnson and Johnson | 688,169 | 12.92 % |
| 3 | Abbvie Inc | 519,284 | 9.75 % |
| 4 | Merck and Co Inc | 364,892 | 6.85 % |
| 5 | Novartis Ag | 1,234 | 5.2% |
| 6 | Abbott Laboratories | 1,234 | 5.2% |
| 7 | Novo Nordisk A | 1,234 | 5.2% |
| 8 | Pfizer Inc | 1,234 | 5.2% |
| 9 | Astrazeneca Plc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 0 | Esperion Therapeutics Inc | 799 | 0.00 % |
Market cap and industry share for the rest of Esperion Therapeutics Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-07-14.
Esperion Therapeutics Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (446 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 0.00 % | 37.92 % (avg) | -37.9 pp |
| Operating Margin | 18.12 % | industry median | +17.0 pp |
| EBITDA Margin | 10.23 % | -6.30 % (avg) | +16.5 pp |
| Capital Intensity (Capex / Revenue) | 0.05 % | 7.51 % (avg) | -7.5 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Esperion Therapeutics Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (446 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.5x | - |
| EV / EBITDA | 22.1x | 15.4x | +6.7x |
| P/B | -2.1x | 4.2x | -6.4x |
| Return on Equity | - | industry aggregate | - |
| Return on Invested Capital | - | -9.78 % (avg) | - |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Esperion Therapeutics Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | - | - | 53.37 % | -65.52 % | -3.79 % | 54.14 % | 185.66 % | 21.31 % |
| Operating Margin | - | -62.75 % | -53.35 % | -289.02 % | -237.83 % | - | 16.37 % | 14.95 % |
| Return on Invested Capital | -68.09 % | -31.83 % | -66.07 % | - | - | - | - | - |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Esperion Therapeutics Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 983 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 0.05 % vs industry average 7.51 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Esperion Therapeutics Inc's dedicated Suppliers and Customers pages, not here.
Esperion Therapeutics Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Esperion Therapeutics Inc falls in the Low attractiveness / High strength cell: Selective.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Esperion Therapeutics Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 17.0 points above the industry median.
Weaknesses
- Latest-quarter revenue run-rate is decelerating (-23.4% annualized vs trailing 12 months).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (48.00 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-6.7% annualized).
Methodology: see Methodology: SWOT Analysis.
Esperion Therapeutics Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Esperion Therapeutics Inc | 0.40 | 1.29 | - |
| Eli Lilly And Company | 0.16 | 1.44 | 1.44 |
| Akari Therapeutics Plc | 0.23 | 0.26 | 0.04 |
| Johnson and Johnson | 0.36 | 1.04 | 0.60 |
| Abbvie Inc | 0.19 | 0.79 | - |
| Merck and Co Inc | 0.40 | 1.46 | 1.01 |
Sign in to see all peers for Esperion Therapeutics Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Esperion Therapeutics Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Esperion Therapeutics Inc | Q1 2026 | +23.2 % | - |
| Eli Lilly And Company | Q3 2026 | +38.6 % | +15.6 % |
| Akari Therapeutics Plc | Q1 2026 | - | - |
| Johnson and Johnson | Q3 2026 | +5.9 % | -95.9 % |
| Abbvie Inc | Q3 2026 | +10.3 % | +2,143.6 % |
| Merck and Co Inc | Q2 2026 | +5.1 % | - |
| PEERS TOTAL | +10.7 % | +14.8 % |
Sign in to see all peers for Esperion Therapeutics Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Esperion Therapeutics Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Esperion Therapeutics Inc | Q1 2026 | - | - |
| Eli Lilly And Company | Q3 2026 | +30.7 % | +52.2 % |
| Akari Therapeutics Plc | Q1 2026 | - | - |
| Johnson and Johnson | Q3 2026 | +10.9 % | +17.7 % |
| Abbvie Inc | Q3 2026 | -19.2 % | -21.0 % |
| Merck and Co Inc | Q2 2026 | +23.6 % | +16.9 % |
Sign in to see all peers for Esperion Therapeutics Inc .
Esperion Therapeutics Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Esperion Therapeutics Inc | - | - | - |
| Eli Lilly And Company | 21.24% | 32.00% | 83.65% |
| Akari Therapeutics Plc | - | - | - |
| Johnson and Johnson | 8.06% | 10.53% | 19.55% |
| Abbvie Inc | 7.48% | 12.87% | - |
| Merck and Co Inc | 2.42% | 3.24% | 6.59% |
Sign in to see all peers for Esperion Therapeutics Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Esperion Therapeutics Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Esperion Therapeutics Inc | - | 1.91 |
| Eli Lilly And Company | 46.50 | 14.80 |
| Akari Therapeutics Plc | - | - |
| Johnson and Johnson | 42.48 | 6.92 |
| Abbvie Inc | 50.58 | 7.89 |
| Merck and Co Inc | 119.39 | 5.49 |
| PEERS AVERAGE | 46.30 | 7.35 |
Sign in to see all peers for Esperion Therapeutics Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.